Table 1.
Baseline subject characteristics
| Long COVID (n = 13) | Controls (n = 25) | P value | |
|---|---|---|---|
| Sex (male, %) | 5 (38.5%) | 11 (44%) | 0.016 |
| Age (mean, std, year) | 47.2 (13.09) | 57.3 (15.5) | 0.024 |
| BMI status (mean, std, kg/m2) | 24.11 (4.09) | 24.62 (3.89) | 0.89 |
| Pre-PET glycaemia (mmol/L) | 5.33 (1.31) | 5.96 (1.91) | 0.23 |
| Administered [18F]FDG activity (MBq) | 123.87 (34.35) | 132.93 (38.46) | 0.58 |
| Interval time between [18F]FDG injection and image acquisition (min) | 51.38 (8.49) | 48.52 (5.96) | 0.44 |
| Symptoms | |||
| Fatigue | 13 | 0 | |
| Pain | 6 | 0 | |
| Dyspnoea | 4 | 0 | |
| Loss of strength | 3 | 0 | |
| Comorbidities (n) | |||
| No | 2 | 4 | |
| Diabetes | 1 | 5 | |
| Hypertension | 2 | 2 | |
| Chronic respiratory disease | 3 | 4 | |
| Concomitant medications (n) | |||
| None | 5 | 9 | |
| Beta-blockers | 0 | 4 | |
| Calcium antagonists | 0 | 3 | |
| Sartans | 0 | 1 | |
| ACE inhibitors | 1 | 2 | |
| Diuretics | 0 | 1 | |
| Oral anticoagulants | 1 | 2 | |
| Antiplatelet drugs | 0 | 1 | |
| Hypoglycaemic drugs | 1 | 3 | |
| Corticosteroids | 2 | 3 | |
| Statins | 1 | 4 | |
| NSAIDs | 3 | 3 | |
| Benzodiazepines | 1 | 2 | |
| Proton pump inhibitors | 4 | 5 | |
| Bronchodilators | 2 | 2 |
ACE, angiotensin-converting enzyme; COVID, coronavirus disease.